Scholar Rock chief commercial officer sells $215k in stock

CAMBRIDGE, MA—Tracey Sacco, the Chief Commercial Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), recently made significant transactions involving the company’s stock. The company, currently valued at $3.16 billion, has seen its shares surge over 280% in the past six months, according to InvestingPro data. On March 24, Sacco sold a total of 6,500 shares of common stock, generating approximately $215,014. The shares were sold at a weighted average price ranging from $32.8917 to $33.7037.

Additionally, Sacco exercised stock options to acquire 5,000 shares at a price of $10 per share, a transaction valued at $50,000. Following these transactions, Sacco holds 71,750 shares of common stock directly, along with additional restricted stock units (RSUs).

These transactions were executed under a pre-established Rule 10b5-1 trading plan, which Sacco adopted in December 2024.

In other recent news, Scholar Rock has announced several key developments that are drawing attention from investors. The company reported a significant earnings miss for the fourth quarter of 2024, with actual earnings per share (EPS) of -$2.47 compared to an expected -$0.58. Despite this, the company’s stock saw a positive response from investors, likely due to the anticipation of future product launches and strategic advancements. Scholar Rock is preparing for a potential commercial launch of its spinal muscular atrophy (SMA) treatment, apitegromab, in the U.S. by the fourth quarter of 2025, with a European launch expected in 2026.

The U.S. Food and Drug Administration (FDA) has granted priority review to Scholar Rock’s Biologics License Application for apitegromab, indicating the treatment’s potential to offer significant improvements over existing therapies for SMA. The European Medicines Agency (EMA) is also reviewing the company’s Marketing Authorization Application for the same treatment. Truist Securities has reiterated a Buy rating on Scholar Rock, maintaining a $45 price target, supported by the FDA’s priority review and the EMA’s acceptance of the application.

Additionally, Scholar Rock has issued inducement equity awards to seven new employees, consisting of stock options and restricted stock units, as part of its strategy to attract new talent. The company’s focus on developing treatments for serious diseases, particularly in the neuromuscular field, continues to drive its growth initiatives. As Scholar Rock progresses with its regulatory and commercial plans, the company’s strategic focus remains on advancing its innovative therapies to meet unmet medical needs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.